Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-06-05

Clinical Trial Update: Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of photon radiotherapy with tremelimumab and durvalumab for BCLC stage B and C hepatocellular carcinoma. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Durvalumab (durvalumab)
  • Tremelimumab (tremelimumab)

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: HCC - Hepatocellular Carcinoma, Tremelimumab | Phase 2 | Status: RECRUITING